Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|April 28, 2014

New Data Links Certification to Greater Clinical Research Site Profitability

Groundbreaking site benchmarking data proves that sites with more staff certified are more profitable than those with fewer staff certified.

Groundbreaking site benchmarking data proves that sites with more staff certified are more profitable than those with fewer staff certified.

“This data validates that investing in ACRP Certification of site staff will attract more studies and lead to greater site profitability,” says James D. Thomasell, Executive Director of ACRP. “This is definitive data on how ACRP Certification positively impacts performance at the site level.”

Data shows that:

· Clinical trial sites with greater numbers of certified staff initiated three times as many trials (20.9 on average) as those with fewer certified staff (6.9) in 2013;

· Clinical trial sites with greater numbers of certified staff averaged $1.6 million in study grants invoiced in 2013, versus $466,000 for sites with fewer certified staff; and

· Clinical trial sites with greater numbers of certified staff reported greater operating profit (18.2%) than those with fewer certified staff (13.9%) in 2013.

This data, which is the result of a joint site survey conducted by ACRP and CenterWatch, a leading provider of clinical trials information, was announced this weekend as part of the inaugural ACRP Site Strategy Forum in San Antonio, Texas, as part of the ACRP 2014 Global Conference & Exhibition.

“We included certification as a component of the site survey in order to establish a benchmark for sites and can now confirm a direct and significant correlation between certification and site performance,” says Kenneth Getz, Founder and Owner of CenterWatch and Director of Sponsored Research Programs for the Center for the Study of Drug Development at the Tufts University School of Medicine.

“I am so pleased that CenterWatch and ACRP collaborated on the site operations survey as part of our overall partnership,” says Joan A. Chambers, COO of CenterWatch, “and are able to provide survey results relating not only to certification, but to risk based monitoring and overall site operations.”

Final benchmarking data will be available mid-summer 2014.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.